A Phase II Study of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-Grade and Anaplastic Ependymoma in Adults

Protocol
11-146
Full Title
Phase II Trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults (CERN 09-02)
Phase
II
Purpose

Ependymomas are tumors of the brain or spinal cord. Carboplatin is a drug commonly used to treat several types of cancer. Bevacizumab is a drug that works by inhibiting the growth of the blood vessels that tumors need to grow and spread. In this study, investigators are assessing the safety and effectiveness of combination therapy with carboplatin and bevacizumab in patients with ependymoma of the brain or spinal cord.

Bevacizumab is approved for treating gliomas and other cancers, but its use in combination with carboplatin in patients with ependymoma is considered investigational.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have a confirmed diagnosis of intracranial or spinal ependymoma or anaplastic ependymoma that has continued to grow despite at least one regimen of chemotherapy.
  • Patients must have recovered from the side effects of prior therapies. At least 4 weeks must have passed since completion of prior chemotherapy or major surgery and 6 weeks since any radiation therapy.
  • Patients may have had prior carboplatin but not bevacizumab.
  • Patients must be age 18 or older.

For more information about this study and to inquire about eligibility, please contact Dr. Antonio Omuro at 212-639-7523.

Disease(s)
Brain Tumors, Primary
Pediatric Brain Tumors: Brain Cancer

Cancer Clinical Trials: Personalizing for Each Patient

Join our experts for a discussion of clinical trials on November 18. Clinical trials can give patients access to new drugs and other treatments before they are widely available, but how do you know if a trial is right for you?

Learn more »